Sociedad Americana de Hirudoterapia

Prognostic factors for attempted finger replantation and revascularisation

Retrospective study published in J Hand Surg Asian Pac Vol (2023)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportEnsayos clínicosLu et al. · The journal of hand surgery Asian-Pacific volume, 2023

Abstract

Background: The aim of this study was to evaluate the impact of variant factors on finger replantation and revascularisation after traumatic amputation, which also included duty shift and the level of main operator. Methods: To determine the prognostic factors for the survival rate of finger replantation and revascularisation after traumatic finger amputation, we retrospectively reviewed the cases of finger replantation conducted from January 2001 to December 2017. Data collected consisted of the basic information of the patients, trauma-related factors, details of the operation and treatment outcomes. Descriptive statistics and data analysis was performed to assess outcomes. Results: In total, 150 patients with 198 replanted digits were enrolled in this study. The median age of the participants was 42.5 years, and 132 (88%) patients were men. The overall successful replantation rate was 86.4%. Seventy-three (36.9%) digits had Yamano type 1 injury; 110 (55.6%), Yamano type 2 injury and 15 (7.6%), Yamano type 3 injury. In total, 73 (36.9%) digits were completely amputated and 125 (63.1%) were not. Half of the replantation procedures (101, 51.0%) were performed during night shift (16:00-00:00), 69 (34.8%) during day shift (08:00-16:00) and 28 (14.1%) during graveyard shift (00:00-08:00). Multivariate logistic regression demonstrated that the trauma mechanism and type of amputation (complete vs. incomplete) significantly affect the survival rate of replantation. Conclusions: The trauma mechanism and type of amputation (complete vs. incomplete) significantly affect the survival rate of replantation. Other factors including duty shift and the level of operator did not reach statistically significance. Further studies must be conducted to validate the results of the current study. Level of Evidence: Level III (Prognostic).

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsMaleHumansAdultFemaleRetrospective StudiesPrognosisAmputation, TraumaticReplantationFinger InjuriesAmputation, Surgical

Resumen

Retrospective analysis of prognostic factors for attempted finger replantation and revascularization outcomes.

Por qué esto importa para la hirudoterapia

This retrospective study reviewed 150 patients (198 digits) who underwent finger replantation or revascularization over a 17-year period, finding an overall success rate of 86.4% and identifying trauma mechanism and completeness of amputation as significant prognostic factors, while duty shift and operator level were not significant. For ASH's domain, the article is relevant only indirectly—digital replantation is a context in which medicinal leech therapy may be used adjunctively for venous congestion—but the abstract does not mention leeches or hirudotherapy. The study focuses on surgical and injury-related prognostic factors. No direct evidence regarding leech therapy or the leech secretome is presented.

Citación

Prognostic factors for attempted finger replantation and revascularisation.

Lu et al. · The journal of hand surgery Asian-Pacific volume, 2023

Contexto clínico relacionado

Explore cómo esta investigación se conecta con la práctica clínica

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.